Uterine carcinoma
diseaseOn this page
Also known as carcinoma of uterusuterus carcinoma
Summary
Uterine carcinoma (MONDO:0005213) is a cancer (an umbrella term covering 9 Mondo subtypes) with 5 GWAS associations across 3 studies and 3 clinical trials. Top therapeutic interventions include carboplatin and azenosertib. A subtype of uterine cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 9 Mondo subtypes
- GWAS associations: 5
- Clinical trials: 3
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | uterine carcinoma |
| Mondo ID | MONDO:0005213 |
| EFO | EFO:0002919 |
| SNOMED CT | 446022000 |
| UMLS | C2960452 |
| MedGen | 755620 |
| Anatomy (UBERON) | UBERON:0000995 |
| Is cancer (heuristic) | yes |
Also known as: carcinoma of uterus · uterus carcinoma
Data availability: 5 GWAS associations (3 studies).
Disease family
This is a subtype of uterine cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › uterine cancer › uterine carcinoma
Related subtypes (6): uterine adnexa cancer, placenta cancer, cervical cancer, uterine corpus cancer, uterine carcinosarcoma, endometrial cancer
Subtypes (9): endometrial carcinoma, uterus carcinoma in situ, cervical carcinoma, endometrial serous adenocarcinoma, squamous cell carcinoma of the corpus uteri, undifferentiated carcinoma of the corpus uteri, papillary carcinoma of the corpus uteri, adenoid cystic carcinoma of the corpus uteri, transitional cell carcinoma of the corpus uteri
Genetics & variants
GWAS landscape
5 GWAS associations across 3 studies. Top hits map to 0 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| chr13:28210761 | 9e-10 | ? | 1.23 | |
| chr6:32447953 | 4e-09 | ? | 0.32 | |
| chr6:31168397 | 2e-08 | ? | 0.43 | |
| chr6:33094275 | 2e-08 | ? | 0.23 | |
| chr6:33046742 | 5e-08 | ? | 0.34 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90041903 | Jiang L | 2021 | 1,143 | 246,365 | A generalized linear mixed model association tool for biobank-scale data. |
| GCST90255401 | Nam K | 2022 | 355 | 45,975 | Genome-wide study on 72,298 individuals in Korean biobank data for 76 traits. |
| GCST90255472 | Nam K | 2022 | 0 | 0 | Genome-wide study on 72,298 individuals in Korean biobank data for 76 traits. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 5 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 0 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 5 |
Functional consequences
| Consequence | Count |
|---|---|
| unknown | 5 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| chr13:28210761 | 9e-10 | Tier 4: intronic/intergenic | ||||||
| chr6:32447953 | 4e-09 | Tier 4: intronic/intergenic | ||||||
| chr6:31168397 | 2e-08 | Tier 4: intronic/intergenic | ||||||
| chr6:33094275 | 2e-08 | Tier 4: intronic/intergenic | ||||||
| chr6:33046742 | 5e-08 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 3.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1/PHASE2 | 1 |
| PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06369155 | PHASE2 | RECRUITING | Azenosertib in Uterine Serous Carcinoma: Biomarker Study |
| NCT04030000 | PHASE1/PHASE2 | WITHDRAWN | Uterine Serous Carcinoma and Adjuvant Combined Intraperitoneal Chemotherapy and Radiation |
| NCT07435987 | Not specified | NOT_YET_RECRUITING | Clinical Feasibility of the ARCHITECT Applicator in Cervical Cancer Brachytherapy |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CARBOPLATIN | 4 | 1 |
| AZENOSERTIB | 2 | 1 |
Related Atlas pages
- Drugs: Carboplatin